The Biden administration faces an April 18 deadline on whether to extend or end a mandate requiring travelers to wear masks on airplanes, trains and in transit hubs.

Top U.S. health officials on March 2 laid out a national blueprint to manage COVID-19 going forward, vowing to prepare for any new variant outbreaks without shutting down schools and businesses and calling for additional funding from Congress.

Laboratory analysis of the antibody-based Covid-19 therapy GlaxoSmithKline is developing with U.S. partner Vir Biotechnology indicated the drug is effective against the new Omicron variant, the British drugmaker said on December 2.

Eli Lilly announced interim proof-of-concept data from the company’s BLAZE-1 Phase II clinical trial of LY-COV555, a neutralizing antibody therapy for Covid-19.

Antibody levels against the novel coronavirus rose and then held steady for up to four months in more than 90% of recovered Covid-19 patients in Iceland, according to a published study.

The United States Food and Drug Administration approved Bayer’s Lampit (nifurtimox) for use in pediatric patients for the treatment of Chagas disease caused by Trypanosoma cruzi.

Researchers at Australia’s Monash University developed a test for SARS-CoV-2, the virus that causes Covid-19, that can provide results in 20 minutes.

Medical device maker Danaher Corp.’s COVID-19 blood test for detecting if a person had ever been infected with the new coronavirus received emergency use clearance from the U.S. Food and Drug Administration.

Many studies assessing the accuracy of COVID-19 antibody tests had major shortcomings, a review concluded, offering further evidence the blood tests are of little use for people seeking to know with certainty if they have been infected.

LabCorp launched a new test that could assess the capacity of antibodies in patient plasma to inhibit the novel coronavirus.